Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Radke

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Science Translational Medicine|June 21, 2023
<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant <i>BRCA</i>-mutant ovarian cancerNitasha Gupta, Tzu-Ting Huang, Jayakumar R Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Head Trauma Rehabilitation|November 9, 2022
An Initial miRNA Profile of Persons With Persisting Neurobehavioral Impairments and States of Disordered Consciousness After Severe Traumatic Brain InjuryMichael J Zilliox, Eileen M Foecking, Gina R Kuffel, et al.
Cancer Research Communications|October 31, 2022
Uterine lavage identifies cancer mutations and increased <i>TP53</i> somatic mutation burden in individuals with ovarian cancerTalayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2022
Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variantsRohit Prakash, Yashpal Rawal, Meghan R Sullivan, et al.
Nature Communications|July 16, 2025
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functionsHayley L Rein, Yashpal Rawal, Anna L Palovcak-Lightbourn, et al.
The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Science Translational Medicine|June 21, 2023
<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant <i>BRCA</i>-mutant ovarian cancerNitasha Gupta, Tzu-Ting Huang, Jayakumar R Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Head Trauma Rehabilitation|November 9, 2022
An Initial miRNA Profile of Persons With Persisting Neurobehavioral Impairments and States of Disordered Consciousness After Severe Traumatic Brain InjuryMichael J Zilliox, Eileen M Foecking, Gina R Kuffel, et al.
Cancer Research Communications|October 31, 2022
Uterine lavage identifies cancer mutations and increased <i>TP53</i> somatic mutation burden in individuals with ovarian cancerTalayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2022
Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variantsRohit Prakash, Yashpal Rawal, Meghan R Sullivan, et al.
Nature Communications|July 16, 2025
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functionsHayley L Rein, Yashpal Rawal, Anna L Palovcak-Lightbourn, et al.
The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Pageof 10